Fig. 2

HAS2-Irinotecan Survival Analysis. a Survival of HAS2 in pooled LGG + GBM, n = 645. KM survival analysis of pooled LGG and GBM patients for HAS2 CNV. Green illustrates increased CNV while red shows decreased CNV and black shows survival for patients with normal copy number. b HAS2 expression and CNV for LGG + GBM, n = 645. Expression values of HAS2 by CNV where group 1 has decreased copy number, group 2 has a normal copy number of HAS2 and group 3 has an increased copy number. There is no statistical difference by t-test between these groups when all LGG and GBM patients are examined. This does not take into account drug exposure. Expression in log 2 (x + 1) form. c Survival analysis of HAS2 CNV and Irinotecan exposure in pooled LGG and GBM patients, n = 76. KM survival curve of LGG and GBM pooled patients exposed to Irinotecan. Green illustrates increased copy number while red shows decreased copy number and black shows survival for patients with normal copy number. Decreased copy number of HAS2 has a distinct decrease in survival when Irinotecan exposure is considered. d HAS2 expression and CNV for pooled LGG + GBM, Irinotecan Exposure, n = 29. Expression values of HAS2 in pooled LGG and GBM patients by CNV where group 1 has decreased copy number, group 2 has a normal copy number of HAS2 and group 3 has an increased copy number. This plot is derived from patients who have expression, CNV, drug and survival data recorded in TCGA. There is a statistical difference in expression (p = .045) between group 1 and group 3, with a close to significant (p = .11) difference between group 1 and group 2